India's New Trial Rules Tick Right Boxes, Shed Interim Compensation Clause
India’s new trial regulations have set competitive approval timelines, provide for local trial exemption in specific instances and also drop a controversial draft clause pertaining to interim compensation payable by sponsors.
You may also be interested in...
India has proposed establishing a Gene Therapy Advisory and Evaluation Committee that will comprise independent experts to monitor all GTP clinical trials.
AstraZeneca’s Calquence, Pfizer’s Lorbrena and Lilly’s Verzenio, which all address unmet medical needs, have been endorsed by an expert panel in India, paving the way for their potential introduction on the market. But all eyes will be on pricing to ensure access in this largely self-pay market.
India has notified a slew of much awaited modifications in its clinical trial compensation regulations including clarifications concerning injury or death due to an investigational product not having its intended therapeutic effect and on the requirement of free medical management for trial-related injury.